1	HOUSE OF REPRESENTATIVES - FLOOR VERSION
2	STATE OF OKLAHOMA
3	1st Session of the 53rd Legislature (2011)
4	COMMITTEE SUBSTITUTE
5	FOR ENGROSSEDSENATE BILL NO. 919By: Sykes of the Senate
6	and
7	Derby and Sanders of the House
8	
9	
10	
11	COMMITTEE SUBSTITUTE
12	An Act relating to narcotics and dangerous drugs; amending 59 O.S. 2001, Section 353.24, as last
13	amended by Section 18, Chapter 321, O.S.L. 2009 (59 O.S. Supp. 2010, Section 353.24), which relates to
14 15	the Oklahoma Pharmacy Act; expanding unlawful conduct to include certain dangerous drugs; providing penalties; amending 63 O.S. 2001, Sections 2-204, as
16	last amended by Section 1, Chapter 182, O.S.L. 2010, 2-206, as last amended by Section 2, Chapter 332,
17	O.S.L. 2008, 2-208, as amended by Section 3, Chapter 283, O.S.L. 2005, 2-210, as last amended by Section
18	3, Chapter 248, O.S.L. 2007, 2-212, as last amended by Section 4, Chapter 458, O.S.L. 2010 and 2-309, as
19	amended by Section 2, Chapter 273, O.S.L. 2008 (63 O.S. Supp. 2010, Sections 2-204, 2-206, 2-208, 2-210,
20	2-212 and 2-309), which relate to the Uniform Controlled Dangerous Substances Act; modifying
21	structure of substances listed within Schedule I; designating certain substances as Schedule I
22	substances; designating certain substances as schedule II substances; designating certain
	substances as schedule III substances; designating
23	certain substances as schedule IV substances; designating certain substance as a schedule V
24	SB919 HFLR Page

1	substance; authorizing electronic prescription method for certain substances under certain circumstances;
2	amending 63 O.S. 2001, Section 2-415, as last amended
3	by Section 5, Chapter 199, O.S.L. 2007 (63 O.S. Supp. 2010, Section 2-415), which relates to the
	Trafficking in Illegal Drugs Act; clarifying weight
4	amounts for certain substances; amending 63 O.S. 2001, Section 2-508, as last amended by Section 15,
5	Chapter 442, O.S.L. 2009 (63 O.S. Supp. 2010, Section 2-508), which relates to the disposition of seized
6	property; modifying agency that shall be responsible for the destruction of seized or surrendered
7	property; amending Section 2, Chapter 458, O.S.L. 2010 (63 O.S. Supp. 2010, Section 2-701), which
8	relates to the Oklahoma State Bureau of Narcotics and
9	Dangerous Drugs Control registry; requiring registration of persons convicted of crimes in other
10	jurisdictions; modifying time limitation for submitting registration form; and providing an
11	effective date.
12	
13	
14	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15	SECTION 1. AMENDATORY 59 O.S. 2001, Section 353.24, as
16	last amended by Section 18, Chapter 321, O.S.L. 2009 (59 O.S. Supp.
17	2010, Section 353.24), is amended to read as follows:
18	Section 353.24 It shall be unlawful for any person, firm or
19	business entity to:
20	1. Forge or increase the quantity of drug in any prescription,
21	or to present a prescription bearing forged, fictitious or altered
22	information or to possess any drug secured by such forged,
23	fictitious or altered prescription;
24	SB919 HFLR Page

Sell, offer for sale, barter or give away any unused
 quantity of drugs obtained by prescription, except through a program
 pursuant to the Utilization of Unused Prescription Medications Act
 or as otherwise provided by the State Board of Pharmacy;

3. Sell, offer for sale, barter or give away any drugs damaged
by fire, water, or other causes without first obtaining the written
approval of the Board or the State Department of Health;

4. Enter into any arrangement whereby prescription orders are 8 9 received, or prescriptions delivered at a place other than the 10 pharmacy in which they are compounded and dispensed. However, nothing in this paragraph shall prevent a pharmacist or an employee 11 of the pharmacy from personally receiving a prescription or 12 delivering a legally filled prescription at a residence, office or 13 place of employment of the patient for whom the prescription was 14 written. Provided further, the provisions of this paragraph shall 15 not apply to any Department of Mental Health and Substance Abuse 16 Services employee or any person whose facility contracts with the 17 Department of Mental Health and Substances Abuse Services whose 18 possession of any dangerous drug, as defined in Section 353.1 of 19 this title, is for the purpose of delivery of a mental health 20 consumer's medicine to the consumer's home or residence. Nothing in 21 this paragraph shall prevent veterinary prescription drugs from 22 being shipped directly from an Oklahoma licensed wholesaler or 23

24

SB919 HFLR

<u>UNDERLINED</u> language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes. Page 3

1 distributor to a client; provided, such drugs may be dispensed only 2 on prescription of a licensed veterinarian and only when an existing 3 veterinary-client-patient relationship exists;

5. Sell, offer for sale or barter or buy any professional 4 5 samples except through a program pursuant to the Utilization of Unused Prescription Medications Act. For purpose of this paragraph, 6 "professional samples" means complimentary drugs packaged in 7 accordance with federal and state statutes and regulations and 8 9 provided to a licensed practitioner free of charge by manufacturers 10 or distributors for the purpose of being distributed free of charge in such package by the licensed practitioner to a patient; 11

Refuse to permit or otherwise prevent members of the Board
or such representatives thereof from entering and inspecting any and
all places, including premises, equipment, contents, and records,
where drugs, medicine, chemicals or poisons are stored, sold,
vended, given away, compounded, dispensed or manufactured;

7. Possess dangerous drugs without a valid prescription or a
valid license to possess such drugs; provided, however, this
provision shall not apply to any Department of Mental Health and
Substance Abuse Services employee or any person whose facility
contracts with the Department of Mental Health and Substances Abuse
Services whose possession of any dangerous drug, as defined in
Section 353.1 of this title, is for the purpose of delivery of a

24

SB919 HFLR

1 mental health consumer's medicine to the consumer's home or 2 residence;

3	8. Possess, sell, offer for sale, barter or give away any	r -
4	quantity of dangerous drugs not listed as a scheduled drug pur	suant
5	to Sections 2-201 through 2-212 of Title 63 of the Oklahoma St	atutes
6	when obtained by prescription bearing forged, fictitious or al	tered
7	information.	
8	a. A first violation of this section shall constitu	ite a
9	misdemeanor and upon conviction shall be punisha	ble by
10	imprisonment in the county jail for a term not m	lore
11	than one (1) year and a fine in an amount not mo	ore
12	than One Thousand Dollars (\$1,000.00).	
13	b. <u>A second violation of this section shall constit</u>	ute a
14	felony and upon conviction shall be punishable b	<u>vy</u>
15	imprisonment in the Department of Corrections for	or a
16	term not exceeding five (5) years and a fine in	an
17	amount not more than Two Thousand Dollars (\$2,00	0.00);
18	<u>9.</u> Knowingly violate a Board order or agreed order;	
19	9.10. Compromise the security of licensure examination	
20	materials; or	
21	$\frac{10.11}{11.}$ Fail to notify the Board, in writing, within ten	(10)
22	days of an address change.	
23		
24	SB919 HFLR	Page 5
	<u>UNDERLINED</u> language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments.	

Strike thru language denotes deletion from present Statutes.

1	SECTION 2. AMENDATORY 63 O.S. 2001, Section 2-204, as
2	last amended by Section 1, Chapter 182, O.S.L. 2010 (63 O.S. Supp.
3	2010, Section 2-204), is amended to read as follows:
4	Section 2-204. The controlled substances listed in this section
5	are included in Schedule I.
6	A. Any of the following opiates, including their isomers,
7	esters, ethers, salts, and salts of isomers, esters, and ethers,
8	unless specifically excepted, when the existence of these isomers,
9	esters, ethers, and salts is possible within the specific chemical
10	designation:
11	1. Acetylmethadol;
12	2. Allylprodine;
13	3. Alphacetylmethadol;
14	4. Alphameprodine;
15	5. Alphamethadol;
16	6. Benzethidine;
17	7. Betacetylmethadol;
18	8. Betameprodine;
19	9. Betamethadol;
20	10. Betaprodine;
21	11. Clonitazene;
22	12. Dextromoramide;
23	13. Dextrorphan (except its methyl ether);
24	SB919 HFLR Page 6

1	14.	Diampromide;
2	15.	Diethylthiambutene;
3	16.	Dimenoxadol;
4	17.	Dimepheptanol;
5	18.	Dimethylthiambutene;
6	19.	Dioxaphetyl butyrate;
7	20.	Dipipanone;
8	21.	Ethylmethylthiambutene;
9	22.	Etonitazene;
10	23.	Etoxeridine;
11	24.	Furethidine;
12	25.	Hydroxypethidine;
13	26.	Ketobemidone;
14	27.	Levomoramide;
15	28.	Levophenacylmorphan;
16	29.	Morpheridine;
17	30.	Noracymethadol;
18	31.	Norlevorphanol;
19	32.	Normethadone;
20	33.	Norpipanone;
21	34.	Phenadoxone;
22	35.	Phenampromide;
23	36.	Phenomorphan;
24	SB919 HFLR	

1	37. Phenoperidine;
2	38. Piritramide;
3	39. Proheptazine;
4	40. Properidine;
5	41. Racemoramide; <u>or</u>
6	42. Trimeperidine ;
7	43. Flunitrazepam;
8	44. B hydroxy amphetamine;
9	45. B-ketoamphetamine;
10	46. 3,4 methylenedioxy N methyl B ketoamphetamine;
11	47. 2,5-dimethoxy-4-methylamphetamine;
12	48. 2,5 dimethoxy 4 bromoamphetamine;
13	49. 2,5-dimethoxy-4-nitroamphetamine;
14	50. 2,5 dimethoxy 4 bromophenethylamine;
15	51. 2,5-dimethoxy-4-chlorophenethylamine;
16	52. 2,5 dimethoxy 4 iodoamphetamine;
17	53. 2,5-dimethoxy-4-iodophenethylamine;
18	54. 2,5 dimethoxy 4 methylphenethylamine;
19	55. 2,5-dimethoxy-4-ethylphenethylamine;
20	56. 2,5 dimethoxy 4 fluorophenethylamine;
21	57. 2,5-dimethoxy-4-nitrophenethylamine;
22	58. 2,5 dimethoxy 4 ethylthio phenethylamine;
23	59. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
24	
21 22 23	57. 2,5-dimethoxy-4-nitrophenethylamine; 58. 2,5 dimethoxy 4 ethylthio phenethylamine;

SB919 HFLR

- 1 60. 2,5-dimethoxy-4-propylthio-phenethylamine;
- 2 61. 2,5 dimethoxy 4 cyclopropylmethylthio phenethylamine;
- 3 62. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
- 4 63. 2,5 dimethoxy 4 (2 fluoroethylthio) phenethylamine;
- 5 64. 5-methoxy-N, N-dimethyltryptamine;
- 6 65. N methyltryptamine;
- 7 <u>66. A-ethyltryptamine;</u>
- 8 67. A methyltryptamine;
- 9 68. N, N-diethyltryptamine;
- 10 69. N, N diisopropyltryptamine;
- 11 70. N, N-dipropyltryptamine;
- 12 71. 5 methoxy a methyltryptamine;
- 13 72. 4-hydroxy-N, N-diethyltryptamine;
- 14 73. 4 hydroxy N, N diisopropyltryptamine;
- 15 74. 5-methoxy-N, N-diisopropyltryptamine; or
- 16 75. 4 hydroxy N isopropyl N methyltryptamine.
- B. Any of the following opium derivatives, their salts,

18 isomers, and salts of isomers, unless specifically excepted, when

19 the existence of these salts, isomers, and salts of isomers is

- 20 possible within the specific chemical designation:
- 21 1. Acetorphine;
- 22 2. Acetyldihydrocodeine;
- 3. Benzylmorphine;
- 24
- SB919 HFLR

1	4. Codeine methylbromide;
2	5. Codeine-N-Oxide;
3	6. Cyprenorphine;
4	7. Desomorphine;
5	8. Dihydromorphine;
6	9. Etorphine;
7	10. Heroin;
8	11. Hydromorphinol;
9	12. Methyldesorphine;
10	13. Methylhydromorphine;
11	14. Morphine methylbromide;
12	15. Morphine methylsulfonate;
13	16. Morphine-N-Oxide;
14	17. Myrophine;
15	18. Nicocodeine;
16	19. Nicomorphine;
17	20. Normorphine;
18	21. Phoclodine; or
19	22. Thebacon.
20	C. Any material, compound, mixture, or preparation which
21	contains any quantity of the following hallucinogenic substances,
22	their salts, isomers, and salts of isomers, unless specifically
23	
24	SB919 HFLR UNDERLINED language denotes Amendments to present Statutes.

1	excepte	d, when the existence of these salts, isomers, and salts	of
2	isomers	is possible within the specific chemical designation:	
3	1.	Methcathinone;	
4	2.	3, 4-methylenedioxy amphetamine;	
5	3.	3, 4-methylenedioxy methamphetamine;	
6	4.	5-methoxy-3, 4-methylenedioxy amphetamine;	
7	5.	3, 4, 5-trimethoxy amphetamine;	
8	6.	Bufotenine;	
9	7.	Diethyltryptamine;	
10	8.	Dimethyltryptamine;	
11	9.	4-methyl-2, 5-dimethoxyamphetamine;	
12	10.	Ibogaine;	
13	11.	Lysergic acid diethylamide;	
14	12.	Marihuana;	
15	13.	Mescaline;	
16	14.	N-benzylpiperazine;	
17	15.	N-ethyl-3-piperidyl benzilate;	
18	16.	N-methyl-3-piperidyl benzilate;	
19	17.	Psilocybin;	
20	18.	Psilocyn;	
21	19.	2, 5 dimethoxyamphetamine;	
22	20.	4 Bromo-2, 5-dimethoxyamphetamine;	
23	21.	4 methoxyamphetamine;	
24	SB919 HFLR		Page 11
I		UNDERLINED language denotes Amendments to present Statutes.	

1	22.	Cyclohexamine;
2	23.	Salvia Divinorum;
3	24.	Salvinorin A;
4	25.	Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
5	thienyl)	cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
6	TPCP, TC	Ρ;
7	26.	Phencyclidine (PCP);
8	27.	Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
9	Phenycly	clohexyl) - Pyrrolidine, PCPy, PHP;
10	28.	1 (2 [trifluoromethylphenyl]) 1-(3-[trifluorometh-
11	ylphenyl	<pre>]) piperazine;</pre>
12	29.	1 Butyl 3 (1 naphthoyl)indole Flunitrazepam;
13	30.	1-Pentyl-3-(1-naphthoyl)indole <u>B-hydroxy-amphetamine</u> ; or
14	31.	(6aR,10aR) 9 (hydroxymethyl) 6, 6 dimethyl 3 (2-
15	methyloc	tan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol <u>B-</u>
16	ketoamphe	etamine;
17	32.	2,5-dimethoxy-4-nitroamphetamine;
18	33.	2,5-dimethoxy-4-bromophenethylamine;
19	34.	2,5-dimethoxy-4-chlorophenethylamine;
20	35.	2,5-dimethoxy-4-iodoamphetamine;
21	36.	2,5-dimethoxy-4-iodophenethylamine;
22	37.	2,5-dimethoxy-4-methylphenethylamine;
23	38.	2,5-dimethoxy-4-ethylphenethylamine;
24	SB919 HFLR	Page 12
		INDERLINED language denotes Amendments to present Statutes.

1	39. 2,5-dimethoxy-4-fluorophenethylamine;
2	40. 2,5-dimethoxy-4-nitrophenethylamine;
3	41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
4	42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
5	43. 2,5-dimethoxy-4-propylthio-phenethylamine;
6	44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
7	45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
8	46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
9	47. 5-methoxy-N, N-dimethyltryptamine;
10	48. N-methyltryptamine;
11	49. A-ethyltryptamine;
12	50. A-methyltryptamine;
13	51. N, N-diethyltryptamine;
14	52. N, N-diisopropyltryptamine;
15	53. N, N-dipropyltryptamine;
16	54. 5-methoxy-a-methyltryptamine;
17	55. 4-hydroxy-N, N-diethyltryptamine;
18	56. 4-hydroxy-N, N-diisopropyltryptamine;
19	57. 5-methoxy-N, N-diisopropyltryptamine;
20	58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
21	59. 3,4-Methylenedioxymethcathinone (Methylone);
22	60. 3,4-Methyenedioxypyrovalerone (MDPV);
23	61. 4-Methylmethcathinone (Mephedrone);
0.4	

24 sb919 hflr

2

3

62. 4-methoxymethcathinone;

63. 4-Fluoromethcathinone; or

64. 3-Fluoromethcathinone.

D. Unless specifically excepted or unless listed in a different
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having stimulant
or depressant effect on the central nervous system:

8 1. Fenethylline;

9 2. Mecloqualone;

10 3. N-ethylamphetamine;

11 4. Methaqualone;

12 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-13 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium 14 oxybate, and sodium oxybutyrate;

15 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
16 manufactured or promoted for human consumption, with the exception
17 of legitimate food additive and manufacturing purposes;

18 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or 19 manufactured for human consumption, with the exception of legitimate 20 food additive and manufacturing purposes;

8. Gamma Valerolactone (GVL) as packaged, marketed, or
manufactured for human consumption, with the exception of legitimate
food additive and manufacturing purposes; or

24

SB919 HFLR

1 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception 2 of legitimate manufacturing purposes. 3 The following industrial uses of Gamma-Butyrolactone, 4 Ε. 1. 5 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are excluded from all schedules of controlled substances under this 6 title: 7 pesticides, 8 a. 9 b. photochemical etching, electrolytes of small batteries or capacitors, 10 c. viscosity modifiers in polyurethane, 11 d. surface etching of metal coated plastics, 12 e. f. organic paint disbursements for water soluble inks, 13 pH regulators in the dyeing of wool and polyamide 14 g. fibers, 15 foundry chemistry as a catalyst during curing, 16 h. i. curing agents in many coating systems based on 17 urethanes and amides, 18 additives and flavoring agents in food, confectionary, i. 19 and beverage products, 20 k. synthetic fiber and clothing production, 21 1. tetrahydrofuran production, 2.2 gamma butyrolactone production, 23 m. 24 SB919 HFLR

1	n. polybutylene terephthalate resin production,
2	o. polyester raw materials for polyurethane elastomers
3	and foams,
4	p. coating resin raw material, and
5	q. as an intermediate in the manufacture of other
6	chemicals and pharmaceuticals.
7	2. At the request of any person, the Director may exempt any
8	other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
9	Gamma Valerolactone, or 1,4 Butanediol from being included as a
10	Schedule I controlled substance if such product is labeled,
11	marketed, manufactured and distributed for legitimate industrial use
12	in a manner that reduces or eliminates the likelihood of abuse.
13	3. In making a determination regarding an industrial product,
14	the Director, after notice and hearing, shall consider the
15	following:
16	a. the history and current pattern of abuse,
17	b. the name and labeling of the product,
18	c. the intended manner of distribution, advertising and
19	promotion of the product, and
20	d. other factors as may be relevant to and consistent
21	with the public health and safety.
22	4. The hearing shall be held in accordance with the procedures
23	of the Administrative Procedures Act.
24	SB919 HFLR Page 16
	UNDERLINED language denotes Amendments to present Statutes.

1	F. Any quantity of a synthetic chemical compound that
2	is a cannabinoid receptor agonist and mimics the pharmacological
3	effect of naturally occurring substances including:
4	<u>1. JWH-004;</u>
5	2. JWH-007;
6	<u>3. JWH-009</u> ;
7	<u>4. JWH-015;</u>
8	<u>5. JWH-016;</u>
9	<u>6. JWH-018;</u>
10	<u>7. JWH-019;</u>
11	<u>8. JWH-020;</u>
12	<u>9. JWH-030;</u>
13	<u>10. JWH-046;</u>
14	<u>11. JWH-047;</u>
15	<u>12. JWH-048;</u>
16	<u>13. JWH-049;</u>
17	<u>14. JWH-050;</u>
18	<u>15. JWH-070;</u>
19	<u>16. JWH-071;</u>
20	<u>17. JWH-072;</u>
21	<u>18. JWH-073;</u>
22	<u>19. JWH-076;</u>
23	<u>20. JWH-079;</u>
24	

SB919 HFLR

UNDERLINED language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes. Page 17

1	21.	JWH-080;
2	22.	JWH-081;
3	23.	JWH-082;
4	24.	JWH-094;
5	25.	JWH-096;
6	26.	JWH-098;
7	27.	JWH-116;
8	28.	JWH-120;
9	29.	JWH-122;
10	30.	JWH-145;
11	31.	JWH-146;
12	32.	JWH-147;
13	33.	JWH-148;
14	34.	JWH-149;
15	35.	JWH-150;
16	36.	JWH-156;
17	37.	JWH-167;
18	38.	JWH-175;
19	39.	JWH-180;
20	40.	JWH-181;
21	41.	JWH-182;
22	42.	JWH-184;
23	43.	JWH-185;

SB919 HFLR

1	<u>44.</u>	JWH-189;
2	<u>45.</u>	JWH-192;
3	46.	JWH-193;
4	<u>47.</u>	JWH-194;
5	48.	JWH-195;
6	49.	JWH-196;
7	50.	JWH-197;
8	51.	JWH-198;
9	52.	JWH-199;
10	53.	JWH-200;
11	54.	JWH-201;
12	55.	JWH-202;
13	56.	JWH-203;
14	57.	JWH-204;
15	58.	JWH-205;
16	59.	JWH-206;
17	60.	JWH-207;
18	61.	JWH-208;
19	62.	JWH-209;
20	63.	JWH-210;
21	64.	JWH-211;
22	65.	JWH-212;
23	66.	JWH-213;

SB919 HFLR

1	67.	JWH-234;
2	68.	JWH-235;
3	69.	JWH-236;
4	70.	JWH-237;
5	71.	JWH-239;
6	72.	JWH-240;
7	73.	JWH-241;
8	74.	JWH-242;
9	75.	JWH-243;
10	76.	JWH-244;
11	77.	JWH-245;
12	78.	JWH-246;
13	79.	JWH-248;
14	80.	JWH-249;
15	81.	JWH-250;
16	82.	JWH-251;
17	83.	JWH-252;
18	84.	JWH-253;
19	85.	JWH-262;
20	86.	JWH-292;
21	87.	JWH-293;
22	88.	JWH-302;
23	89.	JWH-303;

SB919 HFLR

1	90.	JWH-304;
2	91.	JWH-305;
3	92.	JWH-306;
4	93.	JWH-307;
5	94.	JWH-308;
6	95.	JWH-311;
7	96.	JWH-312;
8	97.	JWH-313;
9	98.	JWH-314;
10	99.	JWH-315;
11	100.	JWH-316;
12	101.	JWH-346;
13	102.	JWH-348;
14	103.	JWH-363;
15	104.	JWH-364;
16	105.	JWH-365;
17	106.	JWH-367;
18	107.	JWH-368;
19	108.	JWH-369;
20	109.	JWH-370;
21	110.	JWH-371;
22	111.	JWH-373;
23	112.	JWH-386;

SB919 HFLR

1	113. JWH-387;
2	<u>114. JWH-392;</u>
3	<u>115. JWH-394;</u>
4	<u>116. JWH-395;</u>
5	<u>117. JWH-397;</u>
6	<u>118. JWH-398;</u>
7	<u>119. JWH-399;</u>
8	<u>120. JWH-400;</u>
9	<u>121. JWH-412;</u>
10	<u>122. JWH-413;</u>
11	<u>123. JWH-414;</u>
12	<u>124. JWH-415;</u>
13	125. CP-55, 940;
14	<u>126. CP-47, 497;</u>
15	<u>127. HU-210;</u>
16	<u>128. HU-211;</u>
17	129. WIN-55, 212-2; and
18	<u>130. AM-2201.</u>
19	SECTION 3. AMENDATORY 63 O.S. 2001, Section 2-206, as
20	last amended by Section 2, Chapter 332, O.S.L. 2008 (63 O.S. Supp.
21	2010, Section 2-206), is amended to read as follows:
22	Section 2-206. The controlled substances listed in this section
23	are included in Schedule II.
24	SB919 HFLR Page 22

A. Any of the following substances except those narcotic drugs listed in other schedules whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

6 1. Opium and opiate, and any salt, compound, derivative, or7 preparation of opium or opiate;

8 2. Any salt, compound, isomer, derivative, or preparation 9 thereof which is chemically equivalent or identical with any of the 10 substances referred to in paragraph 1 of this subsection, but not 11 including the isoquinoline alkaloids of opium;

12

3. Opium poppy and poppy straw; or

4. Coca leaves except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, and salts of isomers; ecgonine, its derivatives, their salts, isomers and salts of isomers; or any compound, mixture or preparation which contains any quantity of any of the substances referred to in this paragraph.

B. Any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters and ethers, when
the existence of these isomers, esters, ethers, and salts is
possible within the specific chemical designation:

24

SB919 HFLR

1	1.	Alphaprodine;
2	2.	Anileridine;
3	3.	Bezitramide;
4	4.	Dihydrocodeine;
5	5.	Diphenoxylate;
6	6.	Fentanyl;
7	7.	Hydromorphone;
8	8.	Isomethadone;
9	9.	Levomethorphan;
10	10.	Levorphanol;
11	11.	Metazocine;
12	12.	Methadone;
13	13.	Methadone - Intermediate, 4-cyano-2-dimethylamino-4, 4-
14 d	diphenyl	l butane;
15	14.	Moramide - Intermediate, 2-methyl-3-morpholino-1, 1-
16 d	diphenyl	l-propane-carboxylic acid;
17	15.	Oxycodone;
18	16.	Oxymorphone;
19	17.	Pethidine (Meperidine);
20	18.	Pethidine - Intermediate - A, 4-cyano-1-methyl-4-
21 g	phenylp	iperidine;
22	19.	Pethidine - Intermediate - B, ethyl-4-phenylpiperidine-4-
23 0	carboxy	late;
24 s	B919 HFLR	Page 24 <u>UNDERLINED</u> language denotes Amendments to present Statutes.
		BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes.

1	20.	Pethidine - Intermediate - C, 1-methyl-4-phenylpiperidine-
2	4-carbox	ylic acid;
3	21.	Phenazocine;
4	22.	Piminodine;
5	23.	Racemethorphan;
6	24.	Racemorphan;
7	25.	Etorphine Hydrochloride salt only;
8	26.	Alfentanil hydrochloride; or
9	27.	Levo-alphacetylmethadol <u>;</u>
10	28.	Codeine;
11	29.	Hydrocodone;
12	<u>30.</u>	Morphine;
13	31.	Remifentanil; or
14	32.	Sufentanil.
15	C.	Any substance which contains any quantity of:
16	1.	Methamphetamine, including its salts, isomers, and salts of
17	isomers;	OT
18	2.	Amphetamine, its salts, optical isomers, and salts of its
19	optical	isomers <u>; or</u>
20	<u>3.</u>	Nabilone.
21	D.	Unless specifically excepted or unless listed in another
22	schedule	, any material, compound, mixture, or preparation, which
23		
24	SB919 HFLR	Page 25
		UNDERLINED language denotes Amendments to present Statutes.

BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes.

1 contains any quantity of the following substances having stimulant or depressant effect on the central nervous system: 2 Phenmetrazine and its salts; 1. 3 Methylphenidate; 4 2. 5 3. Amobarbital; Pentobarbital; or 6 4. 5. Secobarbital. 7 SECTION 4. AMENDATORY 63 O.S. 2001, Section 2-208, as 8 9 amended by Section 3, Chapter 283, O.S.L. 2005 (63 O.S. Supp. 2010, 10 Section 2-208), is amended to read as follows: Section 2-208. The controlled substances listed in this section 11 are included in Schedule III. 12 13 Α. Unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the 14 following substances or any other substance having a potential for 15 abuse associated with a stimulant or depressant effect on the 16 central nervous system: 17 Any substance which contains any quantity of a derivative of 18 1. barbituric acid, or any salt of a derivative of barbituric acid 19 unless specifically excepted or unless listed in another schedule; 20 2. Chlorhexadol; 21 3. Glutethimide; 2.2 4. Lysergic acid; 23 24 SB919 HFLR Page 26 UNDERLINED language denotes Amendments to present Statutes.

BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes.

1	5. Lysergic acid amide;
2	6. Methyprylon;
3	7. Sulfondiethylmethane;
4	8. Sulfonethylmethane;
5	9. Sulfonmethane;
6	10. Benzephetamine and its salts;
7	11. Chlorphentermine and its salts;
8	12. Clortermine;
9	13. Mazindol;
10	14. Phendimetrazine;
11	15. Phenylacetone (P2P);
12	16. 1-Phenycyclohexylamine;
13	17. 1-Piperidinocychexanecarbo nitrile (PCC);
14	18. Ketamine, its salts, isomers, and salts of isomers;
15	19. Any material, compound, mixture, or preparation which
16	contains any quantity of the following hormonal substances or
17	steroids, including their salts, isomers, esters and salts of
18	isomers and esters, when the existence of these salts, isomers,
19	esters, and salts of isomers and esters is possible within the
20	specific chemical designation:
21	a. Boldenone,
22	b. Chlorotestosterone,
23	c. Clostebol,
24	SB919 HFLR
	UNDERLINED language denotes Amendments to present Statutes.

1		d.	Dehydrochlormethyltestosterone,
2		e.	Dihydrotestosterone,
3		f.	Drostanolone,
4		g.	Ethylestrenol,
5		h.	Fluoxymesterone,
6		i.	Formebolone,
7		j.	Mesterolone,
8		k.	Methandienone,
9		1.	Methandranone,
10		m.	Methandriol,
11		n.	Methandrostenolone,
12		ο.	Methenolone,
13		p.	Methyltestosterone, except as provided in subsection E
14			of this section,
15		q.	Mibolerone,
16		r.	Nandrolone,
17		s.	Norethandrolone,
18		t.	Oxandrolone,
19		u.	Oxymesterone,
20		v.	Oxymetholone,
21		W.	Stanolone,
22		x.	Stanozolol,
23		у.	Testolactone,

1	z. Testosterone, except as provided in subsection E of
2	this section, and
3	aa. Trenbolone;
4	20. Tetrahydrocannibinols; or
5	21. Any drug product containing gamma-hydroxybutyric acid,
6	including its salts, isomers, and salts of isomers, for which an
7	application has been approved under Section 505 of the Federal Food,
8	Drug, and Cosmetic Act <u>;</u>
9	22. Buprenorphine; or
10	23. Hydrocodone with another active ingredient.
11	Livestock implants as regulated by the Federal Food and Drug
12	Administration shall be exempt.
13	B. Nalorphine.
14	C. Unless listed in another schedule, any material, compound,
15	mixture, or preparation containing limited quantities of any of the
16	following narcotic drugs, or any salts thereof:
17	1. Not more than one and eight-tenths (1.8) grams of codeine or
18	any of its salts, per one hundred (100) milliliters or not more than
19	ninety (90) milligrams per dosage unit, with an equal or greater
20	quantity of an isoquinoline alkaloid of opium;
21	2. Not more than one and eight-tenths (1.8) grams of codeine or
22	any of its salts, per one hundred (100) milliliters or not more than
23	
24	SB919 HFLR <u>UNDERLINED</u> language denotes Amendments to present Statutes.

ninety (90) milligrams per dosage unit, with one or more active,
 nonnarcotic ingredients in recognized therapeutic amounts;

3 3. Not more than three hundred (300) milligrams of
4 dihydrocodeinone or any of its salts, per one hundred (100)
5 milliliters or not more than fifteen (15) milligrams per dosage
6 unit, with a fourfold or greater quantity of an isoquinoline
7 alkaloid of opium;

8 4. Not more than three hundred (300) milligrams of
9 dihydrocodeinone or any of its salts, per one hundred (100)
10 milliliters or not more than fifteen (15) milligrams per dosage
11 unit, with one or more active, nonnarcotic ingredients in recognized
12 therapeutic amounts;

13 5. Not more than one and eight-tenths (1.8) grams of 14 dihydrocodeine or any of its salts, per one hundred (100) 15 milliliters or not more than ninety (90) milligrams per dosage unit, 16 with one or more active, nonnarcotic ingredients in recognized 17 therapeutic amounts;

18 6. 4. Not more than three hundred (300) milligrams of
19 ethylmorphine or any of its salts, per one hundred (100) milliliters
20 or not more than fifteen (15) milligrams per dosage unit, with one
21 or more ingredients in recognized therapeutic amounts;

22 7. 5. Not more than five hundred (500) milligrams of opium per
23 one hundred (100) milliliters or per one hundred (100) grams, or not

24

SB919 HFLR

1 more than twenty-five (25) milligrams per dosage unit, with one or 2 more active, nonnarcotic ingredients in recognized therapeutic 3 amounts; or

8. 6. Not more than fifty (50) milligrams of morphine or any of
its salts, per one hundred (100) milliliters or per one hundred
(100) grams with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.

The Board of Pharmacy may except by rule any compound, 8 D. 9 mixture, or preparation containing any stimulant or depressant substance listed in subsections A and B of this section from the 10 application of all or any part of the Uniform Controlled Dangerous 11 12 Substances Act if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or 13 depressant effect on the central nervous system, and if the 14 admixtures are included therein in combinations, quantity, 15 proportion, or concentration that vitiate the potential for abuse of 16 the substances which have a stimulant or depressant effect on the 17 central nervous system. 18

E. The following hormonal substances or steroids are exemptfrom classification as Schedule III controlled dangerous substances:

1. Estratest, containing 1.25 mg esterified estrogens and 2.5
 mg methyltestosterone;

23

24

SB919 HFLR

2. Estratest HS, containing 0.625 mg esterified estrogens and
 1.25 mg methyltestosterone;

Premarin with Methyltestosterone, containing 1.25 mg 3 3. conjugated estrogens and 10.0 mg methyltestosterone; 4 5 4. Premarin with Methyltestosterone, containing 0.625 mg conjugated estrogens and 5.0 mg methyltestosterone; 6 7 Testosterone Cypionate - Estrodiol Cypionate injection, 5. containing 50 mg/ml Testosterone Cypionate; and 8 9 6. Testosterone Enanthate - Estradiol Valerate injection,

10 containing 90 mg/ml Testosterone Enanthate and 4 mg/ml Estradiol
11 Valerate.

SECTION 5. AMENDATORY 63 O.S. 2001, Section 2-210, as last amended by Section 3, Chapter 248, O.S.L. 2007 (63 O.S. Supp. 2010, Section 2-210), is amended to read as follows:

Section 2-210. A. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant or depressant effect on the central nervous system:

19 1. Chloral betaine;

- 20 2. Chloral hydrate;
- 21 3. Ethchlorvynol;
- 22 4. Ethinamate;
- 23 5. Meprobamate;

24

SB919 HFLR

1	6. P	Paraldehyde;
2	7. P	Petrichloral;
3	8. D	Diethylpropion;
4	9. P	Phentermine;
5	10.	Pemoline;
6	11.	Chlordiazepoxide;
7	12.	Chlordiazepoxide and its salts, but not including
8	chlordiaz	epoxide hydrochloride and clidinium bromide or
9	chlordiaz	epoxide and water-soluble esterified estrogens;
10	13.	Diazepam;
11	14.	Oxazepam;
12	15.	Clorazepate;
13	16.	Flurazepam and its salts;
14	17.	Clonazepam;
15	18.	Barbital;
16	19.	Mebutamate;
17	20.	Methohexital;
18	21.	Methylphenobarbital;
19	22.	Phenobarbital;
20	23.	Fenfluramine;
21	24.	Pentazocine;
22	25.	Propoxyphene;
23	26.	Butorphanol;
24	SB919 HFLR	

1	
	27. Alprazolam;
2	28. Halazepam;
3	29. Lorazepam;
4	30. Prazepam;
5	31. Temazepam;
6	32. Triazolam;
7	33. Carisoprodol;
8	34. Ephedrine, its salts, optical isomers, and salts of optical
9	isomers as the only active ingredient, or in combination with other
10	active ingredients; or
11	35. Dichloralphenazone <u>;</u>
12	36. Estazolam;
13	37. Eszopiclone;
14	38. Midazolam;
15	<u>39. Modafinil;</u>
16	40. Zaleplon; or
17	41. Zolpidem.
18	B. 1. The following nonnarcotic substances, which may, under
19	the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301),
20	be lawfully sold over the counter without a prescription, are
21	excluded from all schedules of controlled substances under this
22	title:
23	a. Breathe-Aid,
24	
	SB919 HFLR Page 34

1	b.	BronCare,
2	c.	Bronchial Congestion,
3	d.	Bronkaid Tablets,
4	e.	Bronkaid Dual Action Caplets,
5	f.	Bronkotabs,
6	g.	Bronkolixir,
7	h.	NeoRespin,
8	i.	Pazo Hemorrhoid Ointment and Suppositories,
9	j.	Primatene Tablets,
10	k.	Primatene "Dual Action" Formula,
11	1.	Quelidrine,
12	m.	Resp, and
13	n.	Vatronal Nose Drops.
14	2. At th	ne request of any person, the Director may exempt any
15	other drug pr	roduct containing ephedrine from being included as a
16	Schedule IV c	controlled substance if such product:
17	a.	is labeled and marketed in a manner consistent with
18		the pertinent OTC tentative final or final monograph
19		issued by the FDA, and
20	b.	is manufactured and distributed for legitimate
21		medicinal use and in a manner that reduces or
22		eliminates the likelihood of abuse.
23		
24	SB919 HFLR	Page
UNDERLINED language denotes Amendments to present Statutes.		

BOLD FACE CAPITALIZED language denotes deletion from present Statutes.

1 3. In making a determination regarding a drug product, the Director, after notice and hearing, shall consider the following: 2 the history and current pattern of abuse, 3 a. b. the name and labeling of the product, 4 5 c. the intended manner of distribution, advertising and promotion of the product, and 6 d. other factors as may be relevant to and consistent 7 with the public health and safety. 8 9 4. The hearing shall be held in accordance with the Administrative Procedures Act. 10 5. A list of current drug products meeting exemption 11 12 requirements under this subsection may be obtained from the Bureau upon written request. 13 C. The Board of Pharmacy may except by rule any compound, 14 mixture, or preparation containing any depressant substance listed 15 in subsection A of this section from the application of all or any 16 part of the Uniform Controlled Dangerous Substances Act, Section 2-17 101 et seq. of this title, if the compound, mixture, or preparation 18 contains one or more active medicinal ingredients not having a 19 depressant effect on the central nervous system, and if the 20 admixtures are included therein in combinations, quantity, 21 proportion, or concentration that vitiate the potential for abuse of 2.2 23

24

SB919 HFLR

the substances which have a depressant effect on the central nervous
 system.

3 SECTION 6. AMENDATORY 63 O.S. 2001, Section 2-212, as 4 last amended by Section 4, Chapter 458, O.S.L. 2010 (63 O.S. Supp. 5 2010, Section 2-212), is amended to read as follows:

6 Section 2-212. A. The controlled substances listed in this7 section are included in Schedule V.

8 1. Any compound, mixture, or preparation containing limited
9 quantities of any of the following narcotic drugs, which also
10 contains one or more nonnarcotic active medicinal ingredients in
11 sufficient proportion to confer upon the compound, mixture, or
12 preparation, valuable medicinal qualities other than those possessed
13 by the narcotic drug alone:

14 a. not more than two hundred (200) milligrams of codeine,
15 or any of its salts, per one hundred (100) milliliters
16 or per one hundred (100) grams,

b. not more than one hundred (100) milligrams of
dihydrocodeine, or any of its salts, per one hundred
(100) milliliters or per one hundred (100) grams,

c. not more than one hundred (100) milligrams of
ethylmorphine, or any of its salts, per one hundred
(100) milliliters or per one hundred (100) grams,

23 24

SB919 HFLR

1 d. not more than two and five-tenths (2.5) milligrams of 2 diphenoxylate and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit, or 3 not more than one hundred (100) milligrams of opium 4 e. 5 per one hundred (100) milliliters or per one hundred (100) grams. 6 7 Any compound, mixture, or preparation containing any 2. detectable quantity of pseudoephedrine, its salts or optical 8 9 isomers, or salts of optical isomers. If any compound, mixture, or 10 preparation as specified in this paragraph is dispensed, sold, or distributed in a pharmacy: 11 it shall be dispensed, sold, or distributed only by, 12 a. or under the supervision of, a licensed pharmacist or 13 a registered pharmacy technician, and 14 any person purchasing, receiving, or otherwise 15 b. acquiring any compound, mixture, or preparation shall 16 produce a driver license, passport, military 17 identification, or other state-issued identification 18 card and shall sign a written log, receipt, or other 19 program or mechanism approved by the Oklahoma Bureau 20 of Narcotics and Dangerous Drugs Control, showing: 21 (1)the date of the transaction, 2.2 name of the purchaser, 23 (2)

SB919 HFLR

24

(3) driver license number, passport, military 1 identification, or state-issued identification 2 number and state of residence of the purchaser, 3 (4) name and initials of the pharmacist or pharmacy 4 5 technician conducting the transaction, the product being sold, and (5) 6 total quantity, in grams or milligrams, of 7 (6) pseudoephedrine purchased. 8 9 No person shall purchase, receive, or otherwise acquire more 10 than nine (9) grams of any product, mixture, or preparation within any thirty-day period. Provided, the requirements of this 11 subsection shall not apply to any quantity of such product, mixture 12

14 <u>3. Any compound, mixture, or preparation containing any</u>
15 detectable quantity of pregabalin.

or preparation dispensed pursuant to a valid prescription.

B. The Schedule, as specified in paragraph 2 of subsection A,
shall not apply to any compounds, mixtures, or preparations which
are in liquid, liquid capsule, or gel capsule form if
pseudoephedrine is not the only active ingredient.

C. The Director of the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control, by rule, may exempt other products from
this Schedule which the Director finds are not used in the illegal
manufacture of methamphetamine or other controlled dangerous

24

13

SB919 HFLR

1 substances. A manufacturer of a drug product may apply for removal 2 of the product from the Schedule if the product is determined by the 3 Director to have been formulated in such a way as to effectively 4 prevent the conversion of the active ingredient into 5 methamphetamine.

6

D. As used in this section:

1. "Gel capsule" means any soft gelatin, liquid-filled capsule
that contains a liquid suspension, which, in the case of
pseudoephedrine, is suspended in a matrix of glycerin, polyethylene
glycol, and propylene glycol, along with other liquid substances.
Regardless of product manufacturer labeling, a gelatin-covered solid
does not constitute a gel capsule under this definition; and

2. "Active ingredient" shall include the matrix of glycerin,
 polyethylene glycol, and propylene glycol that is found in liquid
 capsules.

16 SECTION 7. AMENDATORY 63 O.S. 2001, Section 2-309, as 17 amended by Section 2, Chapter 273, O.S.L. 2008 (63 O.S. Supp. 2010, 18 Section 2-309), is amended to read as follows:

Section 2-309. A. 1. Except for dosages medically required for a period not to exceed forty-eight (48) hours which are administered by or on direction of a practitioner, other than a pharmacist, or medication dispensed directly by a practitioner, other than a pharmacist, to an ultimate user, no controlled

24

SB919 HFLR

1 dangerous substance included in Schedule II, which is a prescription drug as determined under regulation promulgated by the Board of 2 Pharmacy, may be dispensed without the written prescription of a 3 practitioner; provided, that, in emergency situations, as prescribed 4 5 by the Board of Pharmacy by regulation, such drug may be dispensed upon oral prescription reduced promptly to writing and filed by the 6 pharmacist in a manner to be prescribed by rules and regulations of 7 the Director. 8

9 2. The transmission of written prescription by practitioner to 10 dispensing pharmacy by facsimile or electronic transmission with 11 electronic signature is permitted only under the following 12 conditions:

a. for Schedule II drugs, the original prescription must
be presented and verified against the facsimile at the
time the substances are actually dispensed, and the
original document must be properly annotated and
retained for filing, except:

18 (1) home infusion pharmacy may consider the facsimile
19 to be a "written prescription" as required by
20 this act and as required by Title 21 U.S.C.,
21 Section 829(a). The facsimile copy of the
22 prescription shall be retained as an original
23 prescription, and it must contain all the

24

SB919 HFLR

information required by this act and 21 CFR, Section 1306.05(a), including date issued, the patient's full name and address, and the practitioner's name, address, DEA registration number, and signature. The exception to the regulations for home infusion/IV therapy is intended to facilitate the means by which home infusion pharmacies obtain prescriptions for patients requiring the frequently modified parenteral controlled release administration of narcotic substances, but does not extend to the dispensing of oral dosage units of controlled substances, and

- (2) the same exception is granted to patients in Long Term Care facilities (LTCF), which are filled by and delivered to the facility by a dispensing pharmacy, and
- 18b.for drugs in Schedules III and IV, a facsimile copy of19a written, signed prescription transmitted directly by20the prescribing practitioner to the pharmacy can serve21as an original prescription. Electronic prescribing22may be utilized for Schedules III and IV subject to

24

23

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

SB919 HFLR

the same requirements as set forth in 21 CFR, Section 1311 et seq.

3 3. Prescriptions shall be retained in conformity with the
4 requirements of this section and Section 2-307 of this title. No
5 prescription for a Schedule II substance may be refilled.

1. Except for dosages medically required for a period not 6 Β. to exceed forty-eight (48) hours which are administered by or on 7 direction of a practitioner, other than a pharmacist, or medication 8 9 dispensed directly by a practitioner, other than a pharmacist, to an 10 ultimate user, no controlled dangerous substance included in Schedule III or IV, which is a prescription drug as determined under 11 12 regulation promulgated by the Board of Pharmacy, may be dispensed without a written or oral prescription. 13

14 2. A written or oral prescription for a controlled dangerous
15 substance in Schedule III or IV may not be filled or refilled more
16 than six (6) months after the date thereof or be refilled more than
17 five times after the date of the prescription, unless renewed by the
18 practitioner.

19 C. No controlled dangerous substance included in Schedule V may 20 be distributed or dispensed other than for a legitimate medical or 21 scientific purpose.

D. Except for dosages medically required for a period not toexceed forty-eight (48) hours which are administered by or on

24

1

2

SB919 HFLR

direction of a practitioner, other than a pharmacist, or medication dispensed directly by a practitioner, other than a pharmacist, to an ultimate user, tincture opium camphorated, commonly known as paregoric, may not be dispensed without a written or oral prescription. The refilling of a prescription for paregoric shall be unlawful unless permission is granted by the prescriber, either written or oral.

8 E. Whenever it appears to the Director that a drug not 9 considered to be a prescription drug under existing state law or 10 regulation of the Board of Pharmacy should be so considered because 11 of its abuse potential, he shall so advise the Board of Pharmacy and 12 furnish to him all available data relevant thereto.

F. "Prescription", as used herein, means a written or oral 13 order by a practitioner to a pharmacist for a controlled dangerous 14 substance for a particular patient, which specifies the date of its 15 issue, and the full name and address of the patient; if the 16 controlled dangerous substance is prescribed for an animal, the 17 species of the animal; the name and quantity of the controlled 18 dangerous substance prescribed; the directions for use; the name and 19 address of the owner of the animal and, if written, the signature of 20 the practitioner. 21

G. No person shall solicit, dispense, receive or deliver anycontrolled dangerous substance through the mail, unless the ultimate

24

SB919 HFLR

1	user is personally known to the practitioner and circumstances			
2	clearly indicate such method of delivery is in the best interest of			
3	the health and welfare of the ultimate user.			
4	SECTION 8. AMENDATORY 63 O.S. 2001, Section 2-415, as			
5	last amended by Section 5, Chapter 199, O.S.L. 2007 (63 O.S. Supp.			
6	2010, Section 2-415), is amended to read as follows:			
7	Section 2-415. A. The provisions of the Trafficking in Illegal			
8	Drugs Act shall apply to persons convicted of violations with			
9	respect to the following substances:			
10	1. Marihuana;			
11	2. Cocaine or coca leaves;			
12	3. Heroin;			
13	4. Amphetamine or methamphetamine;			
14	5. Lysergic acid diethylamide (LSD);			
15	6. Phencyclidine (PCP);			
16	7. Cocaine base, commonly known as "crack" or "rock"; or			
17	8. 3,4-Methylenedioxy methamphetamine, commonly known as			
18	"ecstasy" or MDMA.			
19	B. Except as otherwise authorized by the Uniform Controlled			
20	Dangerous Substances Act, it shall be unlawful for any person to:			
21	1. Knowingly distribute, manufacture, bring into this state or			
22	possess a controlled substance specified in subsection A of this			
23	section in the quantities specified in subsection C of this section;			
24	SB919 HFLR Page 45			

2. Possess any controlled substance with the intent to
 manufacture a controlled substance specified in subsection A of this
 section in quantities specified in subsection C of this section; or

3. Use or solicit the use of services of a person less than
eighteen (18) years of age to distribute or manufacture a controlled
dangerous substance specified in subsection A of this section in
quantities specified in subsection C of this section.

8 Violation of this section shall be known as "trafficking in 9 illegal drugs". Separate types of controlled substances described 10 in subsection A of this section when possessed at the same time in 11 violation of any provision of this section shall constitute a 12 separate offense for each substance.

Any person who commits the conduct described in paragraph 1, 2 or 3 of this subsection and represents the quantity of the controlled substance to be an amount described in subsection C of this section shall be punished under the provisions appropriate for the amount of controlled substance represented, regardless of the actual amount.

19 C. In the case of a violation of the provisions of subsection B 20 of this section, involving:

21 1. Marihuana:

22 23 a. twenty-five (25) pounds or more of a mixture or substance containing a detectable amount of marihuana,

24

SB919 HFLR

- such violation shall be punishable by a fine of not less than Twenty-five Thousand Dollars (\$25,000.00) and not more than One Hundred Thousand Dollars (\$100,000.00), or
- b. one thousand (1,000) pounds or more of a mixture or
 substance containing a detectable amount of marihuana,
 such violation shall be deemed aggravated trafficking
 punishable by a fine of not less than One Hundred
 Thousand Dollars (\$100,000.00) and not more than Five
 Hundred Thousand Dollars (\$500,000.00);

2. Cocaine or coca leaves:

- a. twenty-eight (28) grams or more of a mixture or
 substance containing a detectable amount of cocaine or
 coca leaves, such violation shall be punishable by a
 fine of not less than Twenty-five Thousand Dollars
 (\$25,000.00) and not more than One Hundred Thousand
 Dollars (\$100,000.00),
- b. three hundred (300) grams or more of a mixture or
 substance containing a detectable amount of cocaine or
 coca leaves, such violation shall be punishable by a
 fine of not less than One Hundred Thousand Dollars
 (\$100,000.00) and not more than Five Hundred Thousand
 Dollars (\$500,000.00), or

SB919 HFLR

24

11

1	C.	one (1) pound <u>four hundred fifty (450) grams</u> or more
2		of a mixture or substance containing a detectable
3		amount of cocaine or coca leaves, such violation shall
4		be deemed aggravated trafficking punishable by a fine
5		of not less than One Hundred Thousand Dollars
6		(\$100,000.00) and not more than Five Hundred Thousand
7		Dollars (\$500,000.00);

3. Heroin:

8

- 9 a. ten (10) grams or more of a mixture or substance containing a detectable amount of heroin, such 10 violation shall be punishable by a fine of not less 11 than Twenty-five Thousand Dollars (\$25,000.00) and not 12 more than Fifty Thousand Dollars (\$50,000.00), or 13 twenty-eight (28) grams or more of a mixture or b. 14 substance containing a detectable amount of heroin, 15 such violation shall be punishable by a fine of not 16 less than Fifty Thousand Dollars (\$50,000.00) and not 17 more than Five Hundred Thousand Dollars (\$500,000.00); 18 Amphetamine or methamphetamine: 19 4.
- a. twenty (20) grams or more of a mixture or substance
 containing a detectable amount of amphetamine or
 methamphetamine, such violation shall be punishable by
 a fine of not less than Twenty-five Thousand Dollars

SB919 HFLR

24

(\$25,000.00) and not more than Two Hundred Thousand Dollars (\$200,000.00),

- b. two hundred (200) grams or more of a mixture or
 substance containing a detectable amount of
 amphetamine or methamphetamine, such violation shall
 be punishable by a fine of not less than Fifty
 Thousand Dollars (\$50,000.00) and not more than Five
 Hundred Thousand Dollars (\$500,000.00), or
- 9 c. one (1) pound four hundred fifty (450) grams or more 10 of a mixture or substance containing a detectable 11 amount of amphetamine or methamphetamine, such 12 violation shall be deemed aggravated trafficking 13 punishable by a fine of not less than Fifty Thousand 14 Dollars (\$50,000.00) and not more than Five Hundred 15 Thousand Dollars (\$500,000.00);
 - 5. Lysergic acid diethylamide (LSD):
- 17a.if the quantity involved is not less than fifty (50)18dosage units and not more than one thousand (1,000)19dosage units one (1) gram or more of a mixture or20substance containing a detectable amount of lysergic21acid diethylamide (LSD), such violation shall be22punishable by a fine of not less than Fifty Thousand

23

24

16

1

2

SB919 HFLR

Dollars (\$50,000.00) and not more than One Hundred 1 Thousand Dollars (\$100,000.00), or 2 if the quantity involved is more than one thousand b. 3 (1,000) dosage units ten (10) grams or more of a 4 5 mixture or substance containing a detectable amount of lysergic acid diethylamide (LSD), such violation shall 6 be punishable by a fine of not less than One Hundred 7 Thousand Dollars (\$100,000.00) and not more than Two 8 9 Hundred Fifty Thousand Dollars (\$250,000.00); 6. Phencyclidine (PCP): 10 one (1) ounce twenty (20) grams or more of a substance 11 a. containing a mixture or substance containing a 12 detectable amount of phencyclidine (PCP), such 13 violation shall be punishable by a fine of not less 14 than Twenty Thousand Dollars (\$20,000.00) and not more 15 than Fifty Thousand Dollars (\$50,000.00), or 16 b. eight (8) ounces one hundred fifty (150) grams or more 17 of a substance containing a mixture or substance 18 containing a detectable amount of phencyclidine (PCP), 19 such violation shall be punishable by a fine of not 20 less than Fifty Thousand Dollars (\$50,000.00) and not 21 more than Two Hundred Fifty Thousand Dollars 2.2 (\$250,000.00);23

SB919 HFLR

24

1 7. Cocaine base:

2	a	five (5) grams or more of a mixture or substance
3		described in paragraph 2 of this subsection which
4		contains cocaine base, such violation shall be
5		punishable by a fine of not less than Twenty-five
6		Thousand Dollars (\$25,000.00) and not more than One
7		Hundred Thousand Dollars (\$100,000.00), or
8	b	. fifty (50) grams or more of a mixture or substance
9		described in paragraph 2 of this subsection which
10		contains cocaine base, such violation shall be
11		punishable by a fine of not less than One Hundred
12		Thousand Dollars (\$100,000.00) and not more than Five
13		Hundred Thousand Dollars (\$500,000.00); and
14	8. Me	chylenedioxy methamphetamine:
15	a	. thirty (30) tablets or ten (10) grams of a mixture or
16		substance containing a detectable amount of 3,4-
17		Methylenedioxy methamphetamine, such violation shall
18		be punishable by a fine of not less than Twenty-five
19		Thousand Dollars (\$25,000.00) and not more than One
20		Hundred Thousand Dollars (\$100,000.00), or
21	b	one hundred (100) tablets or thirty (30) grams of a
22		mixture or substance containing a detectable amount of
23		3,4-Methylenedioxy methamphetamine, such violation
24	SB919 HFLR	Page 5
	ALAN CICC	Fage o

shall be punishable by a fine of not less than One Hundred Thousand Dollars (\$100,000.00) and not more than Five Hundred Thousand Dollars (\$500,000.00).
D. Any person who violates the provisions of this section with respect to a controlled substance specified in subsection A of this section in a quantity specified in subsection C of this section
shall, in addition to any fines specified by this section, be

8 punishable by a term of imprisonment as follows:

9 1. Not less than twice the term of imprisonment provided for in
10 Section 2-401 of this title;

If the person has previously been convicted of one violation
 of this section or has been previously convicted of a felony
 violation of the Uniform Controlled Dangerous Substances Act arising
 from separate and distinct transactions, not less than three times
 the term of imprisonment provided for in Section 2-401 of this
 title;

If the person has previously been convicted of two or more
 violations of this section or any provision of the Uniform
 Controlled Dangerous Substances Act which constitutes a felony, or a
 combination of such violations arising out of separate and distinct
 transactions, life without parole; and

4. If the person is convicted of aggravated trafficking asprovided in subparagraph b of paragraph 1 of subsection C of this

24

SB919 HFLR

section, subparagraph c of paragraph 2 of subsection C of this section or subparagraph c of paragraph 4 of subsection C of this section, a mandatory minimum sentence of imprisonment in the custody of the Department of Corrections for a term of fifteen (15) years of which the person shall serve eighty-five percent (85%) of such mandatory sentence before being eligible for parole consideration or any earned credits.

The terms of imprisonment specified in this subsection shall not 8 9 be subject to statutory provisions for suspension, deferral or 10 probation, or state correctional institution earned credits accruing from and after November 1, 1989, except for the achievement earned 11 12 credits authorized by subsection H of Section 138 of Title 57 of the Oklahoma Statutes. To qualify for such achievement credits, such 13 inmates must also be in compliance with the standards for Class 14 level 2 behavior, as defined in subsection D of Section 138 of Title 15 57 of the Oklahoma Statutes. 16

Persons convicted of violations of this section shall not beeligible for appeal bonds.

E. Any person convicted of any offense described in this
section shall, in addition to any fine imposed, pay a special
assessment trauma-care fee of One Hundred Dollars (\$100.00) to be
deposited into the Trauma Care Assistance Revolving Fund created in

23

24

SB919 HFLR

Section 1-2530.9 of this title and the assessment pursuant to
 Section 2-503.2 of this title.

3 SECTION 9. AMENDATORY 63 O.S. 2001, Section 2-508, as 4 last amended by Section 15, Chapter 442, O.S.L. 2009 (63 O.S. Supp. 5 2010, Section 2-508), is amended to read as follows:

Section 2-508. A. Except as otherwise provided, all property 6 described in paragraphs 1 and 2 of subsection A of Section 2-503 of 7 this title which is seized or surrendered pursuant to the provisions 8 9 of the Uniform Controlled Dangerous Substances Act shall be 10 destroyed. The destruction shall be done by or at the direction of the Oklahoma State Bureau of Investigation Narcotics and Dangerous 11 Drugs Control (OSBNDD), who shall have the discretion prior to 12 destruction to preserve samples of the substance for testing. 13 In any county with a population of four hundred thousand (400,000) or 14 more according to the latest Federal Decennial Census, there shall 15 be a located site, approved by the Oklahoma State Bureau of 16 Investigation OSBNDD, for the destruction of the property. Any such 17 property submitted to the Oklahoma State Bureau of Investigation 18 OSBNDD which it deems to be of use for investigative training, 19 educational, or analytical purposes may be retained by the Oklahoma 20 State Bureau of Investigation OSBNDD in lieu of destruction. 21

B. 1. With respect to controlled dangerous substances seizedor surrendered pursuant to the provisions of the Uniform Controlled

24

SB919 HFLR

Dangerous Substances Act, municipal police departments, sheriffs,
 the Oklahoma Bureau of Narcotics and Dangerous Drugs Control
 Commission, the Oklahoma Highway Patrol, and the Oklahoma State
 Bureau of Investigation shall have the authority to destroy seized
 controlled dangerous substances when the amount seized in a single
 incident exceeds ten (10) pounds. The destroying agency shall:

7

8

- a. photograph the seized substance with identifying case numbers or other means of identification,
- 9 b. prepare a report describing the seized substance prior
 10 to the destruction,
- c. retain at least one (1) pound of the substance
 randomly selected from the seized substance for the
 purpose of evidence, and
- d. obtain and retain samples of the substance from enough 14 containers, bales, bricks, or other units of substance 15 seized to establish the presence of a weight of the 16 substance necessary to establish a violation of the 17 Trafficking in Illegal Drugs Act pursuant to 18 subsection C of Section 2-415 of this title, if such a 19 weight is present. If such weight is not present, 20 samples of the substance from each container, bale, 21 brick or other unit of substance seized shall be 2.2 taken. Each sample taken pursuant to this section 23

24

SB919 HFLR

shall be large enough for the destroying agency and
 the defendant or suspect to have an independent test
 performed on the substance for purposes of
 identification.
 If a defendant or suspect is known to the destroying agency,

6 the destroying agency shall give at least seven (7) days' written 7 notice to the defendant, suspect or counsel for the defendant or 8 suspect of:

- 9 a. the date, the time, and the place where the
 10 photographing will take place and notice of the right
 11 to attend the photographing, and
- b. the right to obtain samples of the controlled
 dangerous substance for independent testing and use as
 evidence.

The written notice shall also inform the defendant, suspect 15 3. or counsel for the defendant or suspect that the destroying agency 16 must be notified in writing within seven (7) days from receipt of 17 the notice of the intent of the suspect or defendant to obtain 18 random samples and make arrangements for the taking of samples. 19 The samples for the defendant or suspect must be taken by a person 20 licensed by the Drug Enforcement Administration. If the defendant 21 or counsel for the defendant fails to notify the destroying agency 2.2 in writing of an intent to obtain samples and fails to make 23

24

SB919 HFLR

arrangements for the taking of samples, a sample taken pursuant to
 subparagraph d of paragraph 1 of this subsection shall be made
 available upon request of the defendant or suspect.

The representative samples, the photographs, the reports, and the records made under this section and properly identified shall be admissible in any court or administrative proceeding for any purposes for which the seized substance itself would have been admissible.

9 C. All other property not otherwise provided for in the Uniform Controlled Dangerous Substances Act which has come into the 10 possession of the Oklahoma State Bureau of Narcotics and Dangerous 11 12 Drugs Control, the Department of Public Safety, the Oklahoma State Bureau of Investigation, the Alcoholic Beverage Laws Enforcement 13 Commission, the Department of Corrections, the Office of the 14 Attorney General, or a district attorney may be disposed of by order 15 of the district court when no longer needed in connection with any 16 litigation. If the owner of the property is unknown to the agency 17 or district attorney, the agency or district attorney shall hold the 18 property for at least six (6) months prior to filing a petition for 19 disposal with the district court except for laboratory equipment 20 which may be forfeited when no longer needed in connection with 21 litigation, unless the property is perishable. The Director or 2.2 Commissioner of the agency, the Attorney General, or district 23

24

SB919 HFLR

<u>UNDERLINED</u> language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes. Page 57

1 attorney shall file a petition in the district court of Oklahoma
2 County or in the case of a district attorney, the petition shall be
3 filed in a county within the jurisdiction of the district attorney
4 requesting the authority to:

5

1. Conduct a sale of the property; or

Convert title of the property to the Oklahoma State Bureau
of Narcotics and Dangerous Drugs Control, the Department of Public
Safety, the Oklahoma State Bureau of Investigation, the Alcoholic
Beverage Laws Enforcement Commission, the Department of Corrections,
the Office of the Attorney General, or to the district attorney's
office for the purposes provided for in subsection J, K or L of this
section.

13 The Director, Commissioner, Attorney General or district14 attorney shall attach to the petition:

a. a list describing the property, including all
identifying numbers and marks, if any,

b. the date the property came into the possession of theagency or district attorney, and

19 c. the name and address of the owner, if known.
20 For any item having an apparent value in excess of One Hundred
21 Dollars (\$100.00), but less than Five Hundred Dollars (\$500.00), the
22 notice of the hearing of the petition for the sale of the property,
23 except laboratory equipment used in the processing, manufacturing or

24

SB919 HFLR

1 compounding of controlled dangerous substances in violation of the provisions of the Uniform Controlled Dangerous Substances Act, shall 2 be given to every known owner, as set forth in the petition, by 3 first-class mail to the last-known address of the owner at least ten 4 5 (10) days prior to the date of the hearing. An affidavit of notice being sent shall be filed with the court by a representative of the 6 agency, the Director or Commissioner of the agency, the Attorney 7 General or district attorney. For items in excess of Five Hundred 8 9 Dollars (\$500.00), a notice of the hearing of the petition for the 10 sale of said property shall be delivered to every known owner as set forth in the petition by certified mail. Notice of a hearing on a 11 12 petition for forfeiture or sale of laboratory equipment used in the processing, manufacturing or compounding of controlled dangerous 13 substances in violation of the Uniform Controlled Dangerous 14 Substances Act shall not be required. 15

The notice shall contain a brief description of the property, and 16 the location and date of the hearing. In addition, notice of the 17 hearing shall be posted in three public places in the county, one 18 such place being the county courthouse at the regular place assigned 19 for the posting of legal notices. At the hearing, if no owner 20 appears and establishes ownership of the property, the court may 21 enter an order authorizing the Director, Commissioner, Attorney 22 General, or district attorney to donate the property pursuant to 23

24

SB919 HFLR

<u>UNDERLINED</u> language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes. Page 59

1 subsection J, K or L of this section, to sell the property at a 2 public auction to the highest bidder, or to convert title of the property to the Oklahoma State Bureau of Narcotics and Dangerous 3 Drugs Control, the Department of Public Safety, the Oklahoma State 4 5 Bureau of Investigation, the Alcoholic Beverage Laws Enforcement Commission, the Department of Corrections, or the Office of the 6 Attorney General for the purposes provided for in subsection J, K or 7 L of this section after at least ten (10) days of notice has been 8 9 given by publication in one issue of a legal newspaper of the 10 county. If the property is offered for sale at public auction and no bid is received that exceeds fifty percent (50%) of the value of 11 12 the property, such value to be announced prior to the sale, the Director, Commissioner, Attorney General, or district attorney may 13 refuse to sell the item pursuant to any bid received. The Director, 14 Commissioner, Attorney General, or district attorney shall make a 15 return of the sale and, when confirmed by the court, the order 16 confirming the sale shall vest in the purchaser title to the 17 property so purchased. 18

D. The money received from the sale of property by the Oklahoma
State Bureau of Narcotics and Dangerous Drugs Control shall be used
for general drug enforcement purposes. These funds shall be
transferred to the Bureau of Narcotics Revolving Fund established
pursuant to Section 2-107 of this title or in the case of a district

24

SB919 HFLR

attorney, the revolving fund provided for in paragraph 3 of
 subsection L of Section 2-506 of this title.

At the request of the Department of Public Safety, the Ε. 3 district attorney or a designee of the district attorney may conduct 4 5 any forfeiture proceedings as described in Section 2-503 of this title on any property subject to forfeiture as described in 6 subsection A, B or C of Section 2-503 of this title. 7 The money received from the sale of property by the Department of Public 8 9 Safety shall be deposited in the Department of Public Safety 10 Revolving Fund and shall be expended for law enforcement purposes.

F. The money received from the sale of property by the
Alcoholic Beverage Laws Enforcement Commission shall be deposited in
the General Revenue Fund of the state.

14 G. The money received from the sale of property from the 15 Oklahoma State Bureau of Investigation shall be deposited in the 16 OSBI Revolving Fund and shall be expended for law enforcement 17 purposes.

H. The Director of the Oklahoma Department of Corrections shall make a return of the sale and when confirmed by the court, the order confirming the sale shall vest in the purchaser title to the property so purchased. Twenty-five percent (25%) of the money received from the sale shall be disbursed to a revolving fund in the office of the county treasurer of the county wherein the property

24

SB919 HFLR

was seized, said fund to be used as a revolving fund solely for enforcement of controlled dangerous substances laws, drug abuse prevention and drug abuse education. The remaining seventy-five percent (75%) shall be deposited in the Department of Corrections Revolving Fund to be expended for equipment for probation and parole officers and correctional officers.

The money received from the sale of property from the Office 7 I. of the Attorney General shall be deposited in the Attorney General 8 9 Law Enforcement Revolving Fund and shall be expended for law 10 enforcement purposes. The Office of the Attorney General may enter into agreements with municipal, county or state agencies to return 11 to such an agency a percentage of proceeds of the sale of any 12 property seized by the agency and forfeited under the provisions of 13 this section. 14

Any property, including but not limited to uncontaminated 15 J. laboratory equipment used in the processing, manufacturing or 16 compounding of controlled dangerous substances in violation of the 17 provisions of the Uniform Controlled Dangerous Substances Act, upon 18 a court order, may be donated for classroom or laboratory use by the 19 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, 20 Oklahoma Department of Public Safety, district attorney, the 21 Alcoholic Beverage Laws Enforcement Commission, the Oklahoma 2.2 Department of Corrections, or the Office of the Attorney General to 23

24

SB919 HFLR

any public secondary school or technology center school in this
 state or any institution of higher education within The Oklahoma
 State System of Higher Education.

K. Any vehicle or firearm which has come into the possession 4 5 and title vested in the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, the Oklahoma Department of Public Safety, 6 the Oklahoma State Bureau of Investigation, or the Office of the 7 Attorney General, may be transferred, donated or offered for lease 8 9 to any sheriff's office, tribal law enforcement agency, campus 10 police department pursuant to the provisions of the Oklahoma Campus Security Act, or police department in this state on an annual basis 11 to assist with the enforcement of the provisions of the Uniform 12 Controlled Dangerous Substances Act. Each agency shall promulgate 13 rules, regulations and procedures for leasing vehicles and firearms. 14 No fully automatic weapons will be subject to the leasing agreement. 15 All firearms leased may be utilized only by C.L.E.E.T. certified 16 officers who have received training in the type and class of weapon 17 Every lessee shall be required to submit an annual report 18 leased. to the leasing agency stating the condition of all leased property. 19 A lease agreement may be renewed annually at the option of the 20 leasing agency. Upon termination of a lease agreement, the property 21 shall be returned to the leasing agency for sale or other 2.2 disposition. All funds derived from lease agreements or other 23

24

SB919 HFLR

<u>UNDERLINED</u> language denotes Amendments to present Statutes. BOLD FACE CAPITALIZED language denotes Committee Amendments. Strike thru language denotes deletion from present Statutes. Page 63

disposition of property no longer useful to law enforcement shall be deposited in the agency's revolving fund and shall be expended for law enforcement purposes.

Before disposing of any property pursuant to subsections C 4 L. 5 through I of this section, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, the Department of Public Safety, the 6 Alcoholic Beverage Laws Enforcement Commission, the Oklahoma State 7 Bureau of Investigation, the Department of Corrections, the Office 8 9 of the Attorney General, or a district attorney may transfer or 10 donate the property to another state agency, tribal law enforcement agency, or school district for use upon request. In addition to the 11 provisions of this section, the Oklahoma State Bureau of Narcotics 12 and Dangerous Drugs Control may transfer or donate property for any 13 purpose pursuant to Section 2-106.2 of this title. The agencies and 14 any district attorney that are parties to any transfer of property 15 pursuant to this subsection shall enter into written agreements to 16 carry out any such transfer of property. Any such agreement may 17 also provide for the granting of title to any property being 18 transferred as the parties deem appropriate. If the transfer of 19 property is to a school district, a written agreement shall be 20 entered into with the superintendent of the school district. No 21 weapons may be transferred to a school district except as provided 2.2 for in subsection K of this section. 23

24

SB919 HFLR

1 SECTION 10. AMENDATORY Section 2, Chapter 458, O.S.L. 2 2010 (63 O.S. Supp. 2010, Section 2-701), is amended to read as 3 follows:

There is hereby created within the Oklahoma 4 Section 2-701. Α. 5 State Bureau of Narcotics and Dangerous Drugs Control a registry of persons who, after November 1, 2010, have been convicted, whether 6 upon a verdict or plea of guilty or upon a verdict or plea of nolo 7 contendere, or received a suspended sentence or any deferred or 8 9 probationary term, or are currently serving a sentence or any form 10 of probation or parole for a crime or attempt to commit a crime including, but not limited to, unlawful possession, conspiring, 11 endeavoring, manufacturing, distribution or trafficking of a 12 precursor or methamphetamines under the provisions of Section 2-322, 13 2-332, 2-401, 2-402, 2-408 or 2-415 of Title 63 of the Oklahoma 14 Statutes this title, or any crime including, but not limited to, 15 crimes involving the possession, distribution, manufacturing or 16 trafficking of methamphetamines or illegal amounts of or uses of 17 pseudoephedrine in any federal court, Indian tribal court, or any 18 court of another state if the person is a resident of the State of 19 Oklahoma or seeks to remain in the State of Oklahoma in excess of 20 ten (10) days. 21

B. It shall be unlawful for any person subject to the registrycreated in subsection A of this section to purchase, possess or have

- 24
- SB919 HFLR

1 control of any Schedule V compound, mixture, or preparation containing any detectable quantity of pseudoephedrine, its salts or 2 optical isomers, or salts of optical isomers. As provided in 3 Section 2-212 of Title 63 of the Oklahoma Statutes this title, the 4 5 provisions of this subsection shall not apply to any compounds, mixtures, or preparations which are in liquid, liquid capsule, or 6 gel capsule form if pseudoephedrine is not the only active 7 ingredient. A prescription for pseudoephedrine shall not provide an 8 9 exemption for any person to this law. Any person convicted of 10 violating the provisions of this subsection shall be guilty of a felony, punishable by imprisonment in the custody of the Department 11 of Corrections for not less than two (2) years and not more than ten 12 (10) years, or by a fine of not more than Five Thousand Dollars 13 (\$5,000.00), or by both such fine and imprisonment. 14

The registry created in subsection A of this section shall 15 С. be maintained by the Bureau. The registry shall be made available 16 for registrants who sell or dispense pseudoephedrine-related 17 products and to law enforcement agencies for law enforcement 18 purposes through the Central Repository and the prescription 19 monitoring program. Every registrant selling, dispensing or 20 otherwise delivering pseudoephedrine products shall deny any sale of 21 pseudoephedrine to any individual listed on the methamphetamine 2.2 offender registry. 23

24

SB919 HFLR

1 D. The registry shall consist of the following information:

1. Name of the person;

2

3

2. Date of birth of the person;

3. The offense or offenses which made the person eligible for5 inclusion on the registry;

4. The date of conviction or the date that a plea of guilty or
nolo contendere was accepted by the court for any violation of an
offense provided for in subsection A of this section;

9 5. The county where the offense or offenses occurred; and
10 6. Such other identifying data as the Bureau determines is
11 necessary to properly identify the person.

Beginning November 1, 2010, all district court clerks shall 12 Ε. forward a copy of the judgment and sentence or other applicable 13 information relating to the disposition of the criminal case and 14 date of birth of all persons who are subject to the provisions of 15 this act for a violation of the offenses described in subsection A 16 of this section to the Bureau. The information shall be sent in an 17 electronic format in a manner prescribed by the Bureau within thirty 18 (30) days of the date of final disposition of the case. Every Any 19 person that receives subject to the registry pursuant to subsection 20 A of this section, having received a deferred sentence or is 21 otherwise not in the custody of the Department of Corrections 22 conviction in a federal court, Indian tribal court, or any court of 23

24

SB919 HFLR

1 another state, shall be required to register and submit a methamphetamine offender registration form in a format prescribed by 2 the Bureau within thirty (30) days of entering a plea or receiving a 3 sentence for an offense described in subsection A of this section 4 5 ten (10) days of entering the State of Oklahoma or if incarcerated in a federal institution within the boundaries of Oklahoma, within 6 ten (10) days of release from said institution. Failure to submit 7 the form required by this subsection shall constitute a misdemeanor. 8 9 F. The Bureau shall remove from the registry the name and other identifying information of a person who has been convicted of a 10 violation of any of the offenses described in subsection A of this 11 section ten (10) years after the date of the most recent judgment 12 and sentence. Any person having received a deferred sentence that 13 expires prior to the ten-year time limitation may apply to the 14 Bureau to be removed from the registry upon the completion of the 15 deferred sentence by providing to the Bureau a certified copy of the 16 dismissal of the case by certified mail. The Bureau may remove the 17 person from the registry upon expiration of the deferred sentence. 18

19 G. It shall be a violation for any person to assist another 20 person who is subject to the registry in the purchase of any 21 pseudoephedrine products. Any person convicted of violating the 22 provisions of this subsection shall, for a first offense, be guilty 23 of a misdemeanor, punishable by incarceration in the county jail for

24

SB919 HFLR

1 not more than one (1) year, or by a fine of not more than One Thousand Dollars (\$1,000.00), or by both such fine and imprisonment. 2 Any second or subsequent conviction for a violation of this 3 subsection shall be a felony, punishable by incarceration in the 4 5 custody of the Department of Corrections for not more than two (2) years, or by a fine of not less than Two Thousand Five Hundred 6 Dollars (\$2,500.00) or by both such fine and imprisonment. For the 7 purposes of this subsection, knowledge that a person was subject to 8 9 the methamphetamine offender registry may be proven through court 10 testimony or any other public notice or publicly available record including, but not limited to, court records maintained by the 11 12 Oklahoma Supreme Court Network and the Oklahoma Court Information System. On or prior to November 1, 2011, the Oklahoma State Bureau 13 of Narcotics and Dangerous Drugs Control shall maintain a 14 methamphetamine offender registry website available for viewing by 15 the public. 16 SECTION 11. This act shall become effective November 1, 2011. 17 18 COMMITTEE REPORT BY: COMMITTEE ON PUBLIC SAFETY, dated 03-31-2011 -19 DO PASS, As Amended and Coauthored. 20 21 22 23

24

SB919 HFLR